All Clinical Trials in Georgia

1. Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors
Cancer Type
Eye Cancer
NCI ID
NCT01930968
Protocol IDs
IRB0003943
Treatment Sites (0)
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01871727
Protocol IDs
E7777-G000-302
NCI-2013-00713
Treatment Sites (0)
A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services among Breast Cancer Patients
Cancer Type
Breast Cancer
NCI ID
NCT01789684
Protocol IDs
SCUSF 1102
NCI-2012-02078
Treatment Sites (0)
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Cancer Type
Leukemia
NCI ID
NCT01503632
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03013998
Protocol IDs
BAML-16-001
NCI-2017-00278
Treatment Sites (0)
A Multiarm, Open-label, Multicenter, Phase 1b / 2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
Cancer Type
Lung Cancer
NCI ID
NCT03381274
Protocol IDs
D6070C00004
NCI-2018-00476
Treatment Sites (0)
A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMT CTN #1102)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02016781
Protocol IDs
BMTCTN1102
NCI-2015-00858
2U10HL069294-11
NCI-2014-00100
NCI-2015-00326
Treatment Sites (0)
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03384914
Protocol IDs
MCC-19117
NCI-2018-00290
Treatment Sites (0)
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01656603
Protocol IDs
6637-01
NCI-2016-01676
Treatment Sites (0)
A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Cancer Type
Quality of Life
NCI ID
NCT00948636
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT00668421
Protocol IDs
104
NCI-2012-00298
Treatment Sites (0)
A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03260491
Protocol IDs
U31402-A-U102
NCI-2018-00060
2017-000543-41
Treatment Sites (0)
A Multicenter, Open-Label Phase 1b / 2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Cancer Type
Endometrial Cancer
NCI ID
NCT02501096
Protocol IDs
E7080-A001-111
NCI-2016-00529
Treatment Sites (0)
A Multicenter, Open-Label Study of CMX001 Treatment of Serious Diseases or Conditions Caused By dsDNA Viruses
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT01143181
Protocol IDs
CMX001-350
1986
Treatment Sites (0)
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)
Cancer Type
Melanoma
NCI ID
NCT01511913
Protocol IDs
CA184-143
Treatment Sites (0)
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
Treatment Sites (0)
A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma
NCI ID
NCT03458728
Protocol IDs
19176
NCI-2018-00809
2017-000383-15
Treatment Sites (0)
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
Cancer Type
NCI ID
NCT01787656
Protocol IDs
USA-MCI GON-1.04
NCI-2015-00690
13-005
Treatment Sites (0)
A Phase 1 / 2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With REGN2810, or Isatuximab Alone, in Patients With Advanced Malignancies
Cancer Type
Lung Cancer, Prostate Cancer
NCI ID
NCT03367819
Protocol IDs
ACT15319
NCI-2018-00052
U1111-1197-7792
2017-002846-61
Treatment Sites (0)
A Phase 1 / 2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCI ID
NCT03371979
Protocol IDs
CAEB1102-101B; KEYNOTE PN758
NCI-2017-02397
Treatment Sites (0)
A Phase 1 / 2 Study of VX15 / 2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03320330
Protocol IDs
ADVL1614
ADVL1614
NCI-2017-01103
Treatment Sites (0)
A Phase 1 / 2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03340883
Protocol IDs
ADU-CL-16
NCI-2017-02305
Treatment Sites (0)
A Phase 1 / 2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities
Cancer Type
Colon/Rectal Cancer, Endometrial Cancer, Stomach/ Gastric Cancer
NCI ID
NCT03410927
Protocol IDs
TO-TAS0728-101
NCI-2018-00211
2017-004415-39
Treatment Sites (0)
A Phase 1 / 2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Cancer Type
Unknown Primary
NCI ID
NCT02929862
Protocol IDs
LYC-55716-1001
NCI-2016-01930
LYC-55716
Treatment Sites (0)
A Phase 1 / 2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
Cancer Type
Lymphoma
NCI ID
NCT02264613
Protocol IDs
ALRN-6924-1-01
NCI-2015-00008
ALRN-200-01
Treatment Sites (0)
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Cancer Type
Breast Cancer, Eye Cancer, Non-Hodgkin Lymphoma, Oral Cancer, Unknown Primary
NCI ID
NCT01638533
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
Treatment Sites (0)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
Treatment Sites (0)
A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
Cancer Type
NCI ID
NCT02454010
Protocol IDs
FF21101US101
NCI-2015-01552
Treatment Sites (0)
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed / Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03318861
Protocol IDs
KITE-585-501
NCI-2017-02053
Treatment Sites (0)
A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03374085
Protocol IDs
CC-92480-MM-001
NCI-2018-00132
U1111-1205-3650
2017-001236-19
Treatment Sites (0)
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCI ID
NCT02730312
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03411915
Protocol IDs
XmAb18087-01
NCI-2018-00217
Treatment Sites (0)
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Endometrial Cancer
NCI ID
NCT03517488
Protocol IDs
XmAb20717-01
NCI-2018-00935
DUET-2
Treatment Sites (0)
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03287908
Protocol IDs
20170122
NCI-2017-02084
2017-001997-41
Treatment Sites (0)
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
Treatment Sites (0)
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCI ID
NCT03319940
Protocol IDs
20160323
NCI-2017-02043
Treatment Sites (0)
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and / or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03274219
Protocol IDs
CRB-402
NCI-2017-01861
Treatment Sites (0)
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Cancer Type
NCI ID
NCT02561988
Protocol IDs
BLU-285-2101
NCI-2016-00075
2015-001661-12
Treatment Sites (0)
A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
Cancer Type
Brain Cancer , Unknown Primary
NCI ID
NCT02808650
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (0)
A Phase 1 Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02897375
Protocol IDs
Winship3263-16
NCI-2016-01037
IRB00089583
Treatment Sites (0)
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02922764
Protocol IDs
RGX-104-001
NCI-2017-00226
Treatment Sites (0)
A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Cancer Type
Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02323880
Protocol IDs
ADVL1414
NCI-2014-02410
Treatment Sites (0)
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCI ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
Treatment Sites (0)
A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03486314
Protocol IDs
Pevonedistat-1015
NCI-2018-00640
U1111-1202-2144
Treatment Sites (0)
A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02117219
Protocol IDs
D4190C00007
Treatment Sites (0)
A Phase 1 Study Using Nab-Paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Cancer Type
NCI ID
NCT03507491
Protocol IDs
AFLACST1603
NCI-2018-00465
IRB00098777
Treatment Sites (0)
A Phase 1 Trial using Everolimus in Combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia / Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (0)
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02631044
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Cancer Type
Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer, Unknown Primary
NCI ID
NCT02952989
Protocol IDs
SGN2FF-001
NCI-2016-01822
Treatment Sites (0)
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03415126
Protocol IDs
ASN007-101
NCI-2018-00820
Treatment Sites (0)
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03218683
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02587598
Protocol IDs
INCB 53914-101
NCI-2015-01975
Treatment Sites (0)
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02658890
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
Treatment Sites (0)
A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor
Cancer Type
Lung Cancer
NCI ID
NCT02520778
Protocol IDs
9903
9903
NCI-2015-01270
16-714
Treatment Sites (0)
A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03357627
Protocol IDs
C34008
NCI-2018-00464
2017-002872-14
U1111-1203-9951
Treatment Sites (0)
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Head and Neck Cancer, Lung Cancer, Oral Cancer, Unknown Primary
NCI ID
NCT02834247
Protocol IDs
C34003
NCI-2016-01821
2016-000853-10
U1111-1181-8312
Treatment Sites (0)
A Phase 1b Trial of Neoadjuvant X4P-001 Alone and With Pembrolizumab in Patients With Resectable Melanoma
Cancer Type
Melanoma
NCI ID
NCT02823405
Protocol IDs
X4P-001-MELA
NCI-2016-01133
Treatment Sites (0)
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT02601313
Protocol IDs
KTE-C19-102
NCI-2015-02028
Treatment Sites (0)
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03141684
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
A Phase 2 Study of Durvalumab and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCI ID
NCT02888743
Protocol IDs
Treatment Sites (2)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Lymphoma
NCI ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (0)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Cancer Type
NCI ID
NCT02724579
Protocol IDs
ACNS1422
ACNS1422
NCI-2016-00150
ACNS1422
Treatment Sites (0)
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia
NCI ID
NCT02723994
Protocol IDs
INCB 18424-269
NCI-2016-01687
AALL1521
Treatment Sites (0)
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03190915
Protocol IDs
ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521
Treatment Sites (0)
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02718300
Protocol IDs
INCB 50465-201
NCI-2016-01146
Treatment Sites (0)
A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03565991
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Holly Holtzclaw
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT02935634
Protocol IDs
CA018-003
NCI-2017-00025
2016-002807-24
Treatment Sites (0)
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03397394
Protocol IDs
CO-338-085
NCI-2018-01112
Treatment Sites (0)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02899052
Protocol IDs
M15-538
NCI-2016-01672
Treatment Sites (0)
A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Cancer Type
Leukemia
NCI ID
NCT02520011
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 2, Single Arm, Multicenter, Open Label Trial Combining Optune with Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Cancer Type
Brain Cancer
NCI ID
NCT02847559
Protocol IDs
NU 16C02
NCI-2016-01026
STU00203030
Treatment Sites (0)
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
Treatment Sites (0)
A Phase 2, Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Cancer Type
Hodgkin Lymphoma
NCI ID
NCT01716806
Protocol IDs
Treatment Sites (12)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Holly Holtzclaw
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03301220
Protocol IDs
CR108172
NCI-2018-00062
2016-001205-16
54767414SMM3001
Treatment Sites (0)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Cancer Type
Neuroblastoma
NCI ID
NCT03126916
Protocol IDs
ANBL1531
ANBL1531
NCI-2016-01734
Treatment Sites (0)
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type
Germ Cell Tumor
NCI ID
NCT03067181
Protocol IDs
AGCT1531
AGCT1531
NCI-2017-00178
AGCT1531
Treatment Sites (0)
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03268954
Protocol IDs
Pevonedistat-3001
NCI-2017-02059
U1111-1189-8055
2017-000318-40
JapicCTI-183848
MOH_2018-02-04_002154
Treatment Sites (0)
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Cancer Type
Multiple Myeloma
NCI ID
NCT02312258
Protocol IDs
C16021
NCI-2016-00109
1046003327
153300410A0048
2014-001394-13
JapicCTI-152873
REec-2015-1414
U1111-1160-1702
Treatment Sites (0)